Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
RELMADA THERAPEUTICS, INC.
Last 30 daysInsiders bought $1.67M · 2 buyers, led by Maged Shenouda (CFO) with $843.99K. No qualifying insider sales.
This reflects the filings imported so far, not a complete trading history.
Show all loaded activityThis reflects the filings imported so far, not a complete trading history.
$1,504,791 of common-equity purchase value after transaction-age decay across 180 days.
2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
2 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
A reporting-owner group bought on at least two distinct dates within the cluster window.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.